A comparison of hepatitis B viral markers of patients in different clinical stages of chronic infection

13Citations
Citations of this article
22Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Purpose: Hepatitis B viral markers may be useful for predicting outcomes such as liver-related deaths or development of hepatocellular carcinoma. We determined the frequency of these markers in different clinical stages of chronic hepatitis B infection. Methods: We compared baseline hepatitis B viral markers in 317 patients who were enrolled in a prospective study and identified the frequency of these tests in immune-tolerant (IT) patients, in inactive carriers, and in patients with either hepatitis B e antigen (HBeAg)-positive or HBeAg-negative chronic hepatitis or cirrhosis. Results: IT patients were youngest (median age 27 years) and HBeAg-negative patients with cirrhosis were oldest (median age 58 years) (p = 0.03 to <0.0001). The male to female ratio was similar both in IT patients and in inactive carriers, but there was a male preponderance both in patients with chronic hepatitis and in patients with cirrhosis (p < 0.0001). The A1896 precore mutants were most prevalent in inactive carriers (36.4%) and HBeAg-negative patients with chronic hepatitis (38.8%; p < 0.0001), and the T1762/A1764 basal core promoter mutants were most often detected in HBeAg-negative patients with cirrhosis (65.1%; p = 0.02). Genotype A was detected only in 5.3% of IT patients, and genotype B was least often detected in both HBeAg-Positive patients with chronic hepatitis and cirrhosis (p = 0.03). The hepatitis B viral DNA levels were lowest in inactive carriers (2.69 log10 IU/mL) and highest in IT patients (6.80 log 10 IU/mL; p = 0.02 to <0.0001). At follow-up, HBeAg-positive and HBeAg-negative patients with cirrhosis accounted for 57 of 64 (89.1%) liver-related deaths (p < 0.0001). Conclusion: Differences in baseline hepatitis B viral markers were detected in patients in various clinical stages of hepatitis B virus infection. HBeAg-positive and HBeAg-negative patients with cirrhosis accounted for the majority of the liver-related fatalities. © 2010 The Author(s).

References Powered by Scopus

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA Level

2806Citations
N/AReaders
Get full text

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

1411Citations
N/AReaders
Get full text

Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors

1124Citations
N/AReaders
Get full text

Cited by Powered by Scopus

The management of chronic hepatitis B in Asian Americans

67Citations
N/AReaders
Get full text

Globulin-platelet model predicts minimal fibrosis and cirrhosis in chronic hepatitis B virus infected patients

54Citations
N/AReaders
Get full text

An expert consensus for the management of chronic hepatitis B in Asian Americans

44Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Tong, M. J., Hsu, L., Hsien, C., Kao, J. H., Durazo, F. A., Saab, S., & Blatt, L. M. (2010). A comparison of hepatitis B viral markers of patients in different clinical stages of chronic infection. Hepatology International, 4(2), 516–522. https://doi.org/10.1007/s12072-010-9179-1

Readers over time

‘10‘11‘12‘15‘16‘17‘18‘19‘21‘2302468

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 9

53%

Lecturer / Post doc 4

24%

Researcher 3

18%

Professor / Associate Prof. 1

6%

Readers' Discipline

Tooltip

Medicine and Dentistry 13

72%

Biochemistry, Genetics and Molecular Bi... 2

11%

Immunology and Microbiology 2

11%

Computer Science 1

6%

Save time finding and organizing research with Mendeley

Sign up for free
0